COMMUNIQUÉS West-GlobeNewswire
-
Psychemedics Releases 2026 Workforce Insights Report
30/04/2026 -
Willow Glow Wellness Spa Clinics Announces Advanced LED Facelift Protocol, Attracting Silicon Valley Clients for Non-Surgical Skin Rejuvenation
30/04/2026 -
YouthCommerce Unveils PhiFlow: A Revolutionary Operating Standard for Clinics
30/04/2026 -
Living Carbon secures $500m deal with Octopus Energy Generation to restore degraded land and remove CO₂
30/04/2026 -
Health Catalyst Appoints Steve Nelson, President of Aetna, to Its Board of Directors
30/04/2026 -
Kraig Labs Clears Dual Commercialization Milestones with Record Spider Silk Production and Successful Reeling Operations
30/04/2026 -
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
30/04/2026 -
Former Stryker Medical Division President Brad Saar Joins Sonablate Board to Support Growth of Non-Invasive Prostate Cancer Treatment
30/04/2026 -
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
30/04/2026 -
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
30/04/2026 -
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
30/04/2026 -
New York Blood Center Enterprises and Biohub Launch Collaboration to Advance Cord Blood–Derived Stem Cell Platforms
30/04/2026 -
Alkeus Pharmaceuticals Announces Presentation of Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting
30/04/2026 -
Precision Neuroscience™ Partners With UChicago Medicine Researchers to Advance Brain–Computer Interface Research
30/04/2026 -
A.D.A.M. Innovations Enables Pharmacogenomics for NTT Precision Medicine
30/04/2026 -
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
30/04/2026 -
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
30/04/2026 -
AVITA Medical Names Cary Vance as Chief Executive Officer
30/04/2026 -
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
30/04/2026
Pages